Kura Oncology Announces Acceptance of Two Abstracts for
– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March ......
Kura Oncology to Report Fourth Quarter and Full Year 2022
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the......